Isofol Medical AB, announced that the company invites investors, analysts, and media to a live-streamed R&D Event with a subsequent question and answer session on June 20 at 12:30 CEST.
GOTHENBURG, Sweden, June 14, 2022 /PRNewswire/ -- Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the company invites investors, analysts, and media to a live-streamed R&D Event with a subsequent question and answer session on June 20 at 12:30 CEST.
Isofol will shortly present top-line results from the multi-center, global Phase III AGENT study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC). The purpose of the event is to provide investors, analysts, and media with a better understanding of the current treatment landscape; medical need for colorectal cancer patients; clinical, regulatory and market access demands; and an update on the AGENT study. Speaking at the R&D Event will be Isofol’s CEO Ulf Jungnelius MD, CMO/CSO Roger Tell MD, and Professor Sebastian Stintzing MD, Charité Universitätsmedizin, Division of Hematology, Oncology and Tumor Immunology. The event will be held in English.
Agenda for the R&D Event
- The AGENT study - its design, patient population, endpoints, and an update including the current status of the study and upcoming topline results
- The medical need for colorectal cancer patients
- The current colorectal cancer treatment landscape and the clinical use of current treatments
- Clinical, regulatory, and market access demands for introducing new treatments for colorectal cancer
- Q&A-session
The event will be livestreamed and can be followed via a link that will be published on Isofol’s webpage shortly
Questions can be asked prior to the event by sending an email to info@isofolmedical.com or during the webcast via a chat function. The webcast will also be available on demand on Isofol’s corporate website after the event.
Date and time
June 20, 2022, from 12:30-14:00 p.m. CEST
Webcast link
A link to the webcast will be published on Isofol’s webpage shortly.
For further information, please contact
Isofol Medical AB (publ)
Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55
The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CET on June 14, 2022.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck & Cie, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| 20220614_Isofol_Invitation FoU event_June 20, 2022 |
View original content:https://www.prnewswire.com/news-releases/isofol-invites-to-a-live-streamed-rd-event-on-june-20-at-12-30-cest-301567349.html
SOURCE Isofol Medical AB (publ)
Company Codes: Bloomberg:ISOFOL@SS, ISIN:SE0009581051, RICS:ISOFOL.ST, Stockholm:ISOFOL
